Explore stories from Atlantic Canada.
Watch onFRANKFURT - Germany's diversified group Merck KGaA has raised the prospect of returning to revenue growth next year, recovering from a slump in demand for its specialty materials to produce biotech drugs and semiconductors.
At the group's key biotech process solutions business, which helps drugmakers run cell cultures and bioreactors, large customers would likely stop drawing on inventories and place orders,"with sales picking up again in the first half of the year", it said in a statement. The market for semiconductor materials, for its part, should"recover incrementally in 2024", Merck added.
The company reaffirmed that sales would be broadly flat this year, at between 20.5 billion euros and 21.9 billion euros, compared with 22.2 billion last year.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Merck KGaA says MS drug has blockbuster potential; key data expected in DecemberExplore stories from Atlantic Canada.
Lire la suite »
East Side Mario's robot serving up intrigue in SydneyExplore stories from Atlantic Canada.
Lire la suite »
US business inventories increase in AugustExplore stories from Atlantic Canada.
Lire la suite »
Engaged Capital takes stake in VF Corp, stock jumpsExplore stories from Atlantic Canada.
Lire la suite »
Tesla says US should adopt tougher fuel efficiency rulesExplore stories from Atlantic Canada.
Lire la suite »
U.S. home builder confidence falls to lowest since JanuaryExplore stories from Atlantic Canada.
Lire la suite »